117 related articles for article (PubMed ID: 8823808)
1. Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis.
Bergnes G; Yuan W; Khandekar VS; O'Keefe MM; Martin KJ; Teicher BA; Kaddurah-Daouk R
Oncol Res; 1996; 8(3):121-30. PubMed ID: 8823808
[TBL] [Abstract][Full Text] [Related]
2. Cyclocreatine (1-carboxymethyl-2-iminoimidazolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors.
Lillie JW; O'Keefe M; Valinski H; Hamlin HA; Varban ML; Kaddurah-Daouk R
Cancer Res; 1993 Jul; 53(13):3172-8. PubMed ID: 8319226
[TBL] [Abstract][Full Text] [Related]
3. The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors.
Schimmel L; Khandekar VS; Martin KJ; Riera T; Honan C; Shaw DG; Kaddurah-Daouk R
Anticancer Res; 1996; 16(1):375-80. PubMed ID: 8615639
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells.
Hoosein NM; Martin KJ; Abdul M; Logothetis CJ; Kaddurah-Daouk R
Anticancer Res; 1995; 15(4):1339-42. PubMed ID: 7654018
[TBL] [Abstract][Full Text] [Related]
5. Cell cycle studies of cyclocreatine, a new anticancer agent.
Martin KJ; Winslow ER; Kaddurah-Daouk R
Cancer Res; 1994 Oct; 54(19):5160-5. PubMed ID: 7923134
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
7. Peptides and antitumor activity. Development and investigation of some peptides with antitumor activity.
Teplán I
Acta Biol Hung; 2000; 51(1):1-29. PubMed ID: 10866357
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of creatine analogs produced by alterations in pancreatic hormones and glucose metabolism.
Ara G; Gravelin LM; Kaddurah-Daouk R; Teicher BA
In Vivo; 1998; 12(2):223-31. PubMed ID: 9627806
[TBL] [Abstract][Full Text] [Related]
9. Creatine and cyclocreatine treatment of human colon adenocarcinoma xenografts: 31P and 1H magnetic resonance spectroscopic studies.
Kristensen CA; Askenasy N; Jain RK; Koretsky AP
Br J Cancer; 1999 Jan; 79(2):278-85. PubMed ID: 9888469
[TBL] [Abstract][Full Text] [Related]
10. A novel camptothecin analog with enhanced antitumor activity.
Yount G; Yang Y; Wong B; Wang HJ; Yang LX
Anticancer Res; 2007; 27(5A):3173-8. PubMed ID: 17970058
[TBL] [Abstract][Full Text] [Related]
11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
12. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines.
Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP
Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102
[TBL] [Abstract][Full Text] [Related]
13. Microtubule stabilization and potentiation of taxol activity by the creatine analog cyclocreatine.
Martin KJ; Vassallo CD; Teicher BA; Kaddurah-Daouk R
Anticancer Drugs; 1995 Jun; 6(3):419-26. PubMed ID: 7670140
[TBL] [Abstract][Full Text] [Related]
14. [The selective toxicity of 5-hydroxymethyldeoxyuridine for the cells of human adenocarcinoma of the large intestine].
Lockshin A; Meshcherikova VV
Vopr Onkol; 1989; 35(11):1327-32. PubMed ID: 2609523
[TBL] [Abstract][Full Text] [Related]
15. Progressive decrease of phosphocreatine, creatine and creatine kinase in skeletal muscle upon transformation to sarcoma.
Patra S; Bera S; SinhaRoy S; Ghoshal S; Ray S; Basu A; Schlattner U; Wallimann T; Ray M
FEBS J; 2008 Jun; 275(12):3236-47. PubMed ID: 18485002
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
17. The antitumor activity of the somatostatin structural derivative (TT-232) on different human tumor xenografts.
Tejeda M; Gaal D; Barna K; Csuka O; Kéri G
Anticancer Res; 2003; 23(5A):4061-6. PubMed ID: 14666719
[TBL] [Abstract][Full Text] [Related]
18. 19-nor-26,27-bishomo-vitamin D3 analogs: a unique class of potent inhibitors of proliferation of prostate, breast, and hematopoietic cancer cells.
Kubota T; Koshizuka K; Koike M; Uskokovic M; Miyoshi I; Koeffler HP
Cancer Res; 1998 Aug; 58(15):3370-5. PubMed ID: 9699668
[TBL] [Abstract][Full Text] [Related]
19. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
20. In vivo antitumor activity of choline kinase inhibitors: a novel target for anticancer drug discovery.
Hernández-Alcoceba R; Fernández F; Lacal JC
Cancer Res; 1999 Jul; 59(13):3112-8. PubMed ID: 10397253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
